Novartis raises blockbuster drug forecasts to $18 billion as it seeks to prove growth can last
The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines.
The drugmaker cited strong demand for its blockbuster drugs as it upgraded peak sales forecasts for multiple sclerosis, leukemia, and cholesterol medicines. This story matters for Finance & Markets readers tracking largecap. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. LargecapNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily largecap signal